Category Archives: Mesenchymal Stem Cells

The ideal repair mechanism for cartilage repair and osteoarthritis treatment http://www.stemcellsarthritistreatment.com Is there an ideal repair system for osteoarthritis? Mesenchymal stem cells are the non-blood-derived stem cells fo... By: Nathan Wei … Continue reading →

Are you a candidate for stem treatment for osteoarthritis?... Find out now! http://www.stemcellsarthritistreatment.com http://www.stemcellskneearthritis.com One of the most exciting developments in medicine today is the use of mesenc... By: Nathan Wei … Continue reading →

Stem cell cartilage repair: Lessons from the goat http://www.stemcellsarthritistreatment.com A study by Murphy and colleagues using mesenchymal stem cells in a goat highlighted the regenerative effect of MSC... By: Nathan Wei … Continue reading →

PALO ALTO, Calif., May 17, 2013 /PRNewswire/ --Cellular Biomedicine Group (CBMG) today announced that it has achieved 50% enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To date the trial has had no Severe Adverse Effect (SAE) reported. The Phase I open label clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under number NCT01809769 (click here to view), tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPC in order to reduce inflammation and regenerate damaged joint tissues. This trial is conducted at Shanghai Renji Hospital, one of the largest teaching hospitals in China. "This patient enrollment achievement in our clinical trial is an exciting milestone for CBMG. We anticipate that enrollment will continue to move quickly and the study is on schedule to complete its Phase I clinical trial," said Dr. William Cao, President of Cellular Biomedicine Group. About Cellular Biomedicine GroupCellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, … Continue reading →

Beijing, China (PRWEB) (PRWEB) May 15, 2013 Puhua International Hospitals (PIHs)-Temple of Heaven (http://puhuahospital.com) (http://www.puhuachina.com) has been a leading international neuroscience and biotechnology center in Beijing, China, for the past 20 years. During that time, Puhua has built and maintained a dominant presence in Beijing in the areas of applied biotechnology, neurology, neurosurgery, medicine, cancer, traditional Chinese medicine (TCM) and surgery. PIH also has vigorous programs of Integrative Oncology and Diabetes. Over the past decade Puhua International Hospitals-Temple of Heaven has made huge strides forward in applied cellular biotechnology (stem cell therapy, or SCT). Thus, in addition to its high level of diagnostic and therapeutic expertise, PIH has become a world leader in applied biotechnology, cellular science and applied stem cell technology. It is in these areas of applied clinical research that remarkable progress is being made in the areas of: spinal cord repair; post-traumatic brain injury; cerebral palsy; Parkinsons disease; cerebral-vascular and cardio-vascular disease, and diabetes. By utilizing cellular/regenerative medicine and biotechnology at the time of surgical repair for spinal cord and brain injury, the neurosurgeons and clinical scientists at Puhua International are today redefining what is now possible in terms of recovery from neurological injury and disease. Whereas … Continue reading →

(MENAFN - Muscat Daily) Taking into account the shortcomings of organ transplants and to advance research into stem cell therapy, Sultan Qaboos University Hospital (SQUH) will soon install a quantum bioreactor in its haematology department. The machine is the first of its kind in Oman and in the Middle East, according to Dr Salam bin Salim al Kindi, head of SQUH's haematology department. As cord blood preservation gains popularity, these cost-effective bioreactors can help grow Mesenchymal stem cells (MSCs) in large quantities in a short time and fast-track stem cell experimentation. Manufactured by US-based Terumo Group, this medical technology doesn't need an expensive set-up. ''Usually when you grow stem cells you should follow Good Manufacturing Practice procedures, which is a sterile but expensive set-up. However, all this is not required with the new bioreactor,'' said Dr Kindi. ''It works in a closed system and all you need to do is put the patient's stem cells into the machine. Along with the appropriate nutrients and under proper stimulus, it will reproduce MSCs,'' he added. MSCs can be found in the bone marrow of humans or can be isolated from other sources such as cord blood, peripheral blood, fallopian tube and from … Continue reading →

How can Adult (NonEmbryonic) Mesenchymal Stem Cells help me? The Cell Surgical Network: NonEmbryonic Adult Stem Cells Adult (NonEmbryonic) Mesenchymal Stem Cells are undifferentiated cells that have the ability to repl... By: CellSurgicalNetwork … Continue reading →

Kilian Before After Stemlogix Stem Cell Therapy By: Jim Cain … Continue reading →

What are more factors that help with stem cell osteoarthritis treatment? http://www.stemcellsarthritistreatment.com Kristen Johnson and colleagues reported in Science that molecules that promote the selective differentiation of mesenchymal stem cells (MSCs) into... By: Nathan Wei … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the first quarter of 2013. Highlights and Recent Developments Our team's execution during the first quarter has given us a very strong start to 2013, said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. While we are pleased with our accomplishments, we are focused solely on the future. First Quarter Financial Results Product revenues during the first quarter of 2013 were $4.1 million, compared to $1.1 million during the first quarter of 2012, an increase of 257%. Gross margin during the first quarter was 72% compared to 66% during the first quarter of 2012. Gross profit was $2.9 million during the first quarter of 2013 and $0.75 million during the same period of 2012. We reported a loss of $2.7 million in the first quarter of 2013. As of March 31, 2013, Osiris had $34.9 million in cash, receivables and short-term investments. Research and development expenses for the first quarter of 2013 were $3.0 million, compared to $4.0 million incurred in the … Continue reading →